March 2016 | Targeted Therapies in Oncology

Is Precision Immunology Possible?

April 09, 2016

Clinical Articles

Kaufman recently coined the term "precision immunology" to describe the use of host, immune system and tumor factors as biomarkers to select immunotherapy approaches. But, are we ready to integrate precision immunology into clinical practice?

Cetuximab Improves Long-Term Disease Control in HPV-Negative HNSCC

April 07, 2016

Clinical Articles

Adding cetuximab (Erbitux) to induction chemotherapy and hyperfractionated or accelerated chemoradiation therapy produced long-term control for patients with HPV-, locoregionally advanced head and neck squamous cell carcinoma with a poor prognosis.

Targeted Immunotherapy on Horizon for Brain Tumors

April 06, 2016

Clinical Articles

Despite the letdown of prior research, the future looks bright for immunotherapies and novel targeted approaches for patients with gliomas, many of which have already been developed for other types of cancer.

Possible Treatment on Horizon for Advanced KRAS-Mutant NSCLC

April 05, 2016

Clinical Articles

Promising early phase clinical trials have led to the initiation of the phase III JUNIPER trial, which is assessing abemaciclib (LY2835219) for patients with previously treated KRAS-mutant lung cancer, a traditionally hard to treat genetic subtype.